India has cleared its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to Takeda Biopharmaceuticals India's QDENGA on Monday, 20 July. The approval covers individuals aged 4 to 60 years and marks a landmark shift in the country's public health response to one of its most persistent mosquito-borne disease burdens.

What Makes QDENGA Different

A key distinction of QDENGA is that it does not require pre-vaccination screening to determine prior dengue infection — a requirement that complicated earlier dengue vaccine rollouts globally. Eligible individuals can receive the two-dose regimen regardless of their prior exposure history, simplifying administration at scale.

The vaccine is delivered as two subcutaneous injections of 0.5 ml each, administered three months apart. It is designed to protect against all four dengue virus serotypes, which are simultaneously circulating across several regions of India.

Clinical Evidence Behind the Approval

The DCGI's decision was backed by data from Takeda's global clinical development programme, which comprised 19 Phase I, II and III clinical trials involving more than 28,000 participants across both dengue-endemic and non-endemic countries. Regulators also considered findings from the Phase III DEN-302 trial conducted in India, which specifically evaluated safety and immune response in the 4 to 60 age group.

According to Takeda, long-term follow-up data collected over seven years showed that QDENGA continues to provide protection against dengue infection and dengue-related hospitalisation caused by all four serotypes.

Global Footprint and India Context

Since its global launch in 2022, QDENGA has received approval in 43 countries, with more than 32 million doses distributed worldwide. India's clearance adds one of the world's largest dengue-endemic populations to that footprint.

Mahender Nayak, Head of Intercontinental Markets at Takeda, said: 'This approval marks an important step forward in strengthening dengue prevention in India.'

Goh Choo Beng, Medical Affairs Head for Takeda's Southeast Asia and India Cluster, described the approval as 'an important step in strengthening India's comprehensive approach to dengue prevention, alongside vector control, surveillance, community awareness and other public health measures.'

Why This Matters for India

India consistently ranks among the countries with the highest dengue burden globally, with all four virus serotypes in active circulation. The absence of a licensed vaccine until now left vector control and hospitalisation management as the primary public health tools. QDENGA's approval adds a preventive layer that could reduce severe dengue cases and ease pressure on healthcare infrastructure, particularly during seasonal outbreak peaks.

Notably, the vaccine's screening-free eligibility makes it operationally viable for India's large-scale immunisation infrastructure. Whether QDENGA will be incorporated into the national immunisation programme remains to be seen, and health authorities are expected to outline deployment priorities in the coming months.